3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
fludarabine
6
trametinib
5
Specimen Handling
5
Standard of Care
4
Practice Guidelines as Topic
4
Magnetic Resonance Spectroscopy
4
fludarabine phosphate
3
Whole-Body Irradiation
3
Mycophenolic Acid
3
Melphalan
3
Interviews as Topic
3
GSK2636771
3
Cyclophosphamide
3
Crizotinib
3
Busulfan
3
Biopsy
3
Antilymphocyte Serum
3
AP 1903 reagent
3
venetoclax
2
thymoglobulin
2
palbociclib
2
osimertinib
2
letermovir
2
dabrafenib
2
capivasertib
2
binimetinib
2
adavosertib
2
X-Rays
2
Thiotepa
2
Tacrolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Hematologic Neoplasms
×
bexmarilimab
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled